The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Abstract
The natural history of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected patients has never been studied according to the concept of liver fibrosis progression. The aim of this work was to assess the fibrosis progression rate in HIV-HCV coinfected patients and in patients infected by HCV only. A cohort of 122 HIV-HCV coinfected patients was compared with a control group of 122 HIV-negative HCV-infected patients. Groups were matched according to age, sex, daily alcohol consumption, age at HCV infection, and duration and route of HCV infection. The fibrosis progression rate was defined as the ratio between fibrosis stage (METAVIR scoring system) and the HCV duration. The prevalence of extensive liver fibrosis (METAVIR fibrosis scores 2, 3, and 4) and moderate or severe activity were higher in HIV-infected patients (60% and 54%, respectively) than in control patients (47% and 30%, respectively; P < .05 and P < .001, respectively). The median fibrosis progression rate in coinfected patients and in control patients was 0.153 (95% confidence interval [CI], 0.117-0.181) and 0.106 (95% CI, 0.084-0.125) fibrosis units per year, respectively (P < .0001). HIV seropositivity (P < .0001), alcohol consumption (>50 g/d, P = .0002), age at HCV infection (<25 years old,P< .0001), and severe immunosuppression (CD4 count ≤200 cells/μL,P< .0001) were associated with an increase in the fibrosis progression rate. In coinfected patients, alcohol consumption (>50 g/d), CD4 count (≤200 cells/μL), and age at HCV infection (<25 years old) (P< .0001, respectively) were associated with a higher fibrosis progression rate. HIV seropositivity accelerates HCV-related liver fibrosis progression. In coinfected patients, a low CD4 count, alcohol consumption rate, and age at HCV infection are associated with a higher liver fibrosis progression rate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Self-citationNatural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Self-citationHammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Bedossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,003
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371102 · Cited by 1,885
Soto, B., Sánchez-Quijano, A., Rodrigo, L., Olmo, J. A. D., García-Bengoechea, M., Hernández-Quero, J., Rey, C., Abad, M. A., Rodríguez, M., Sales Gilabert, M., et al. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80001-3 · Cited by 701
Darby, S. C., Ewart, D. W., Giangrande, P. L., Spooner, R. J., Rizza, C. R., Dusheiko, G. M., Lee, C. A., Ludlam, C. A., & Preston, F. E. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05413-5 · Cited by 497
Poynard, T., Bedossa, P., Chevallier, M., Mathurin, P., Lemonnier, C., Trepo, C., Couzigou, P., Payen, J. L., Sajus, M., Costa, J. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322201 · Cited by 458
Self-citationEyster, M. E., Diamondstone, L. S., Lien, J., Ehmann, W. C., Quan, S., & Goedert, J. J. (1993) · PubMed · Cited by 421
Shi, Z., Wakil, A. E., & Rockey, D. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10663 · Cited by 310
Féray, C., Gigou, M., Samuel, D., Paradis, V., Mishiro, S., Maertens, G., Reynés, M., Okamoto, H., Bismuth, H., & Bréchot, C. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90207-4 · Cited by 294
Quantitation of hepatitis C virus RNA in liver transplant recipients
Chazouilleres, O., Kim, M., Combs, C., Ferrell, L., Bacchetti, P., Roberts, J., Ascher, N. L., Neuwald, P., Wilber, J., Urdea, M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90759-5 · Cited by 277
Sobesky, R., Mathurin, P., Charlotte, F., Moussalli, J., Olivi, M., Vidaud, M., Ratziu, V., Opolon, P., & Poynard, T. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70135-6 · Cited by 252
Self-citationEffect of Human Immunodeficiency Virus on Hepatitis C Virus Infection among Injecting Drug Users
Thomas, D. L., Shih, J. W., Alter, H. J., Vlahov, D., Cohn, S., Hoover, D. R., Cheung, L., & Nelson, K. E. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/174.4.690 · Cited by 226
Soriano, V., Garcia-Samaniego, J., Bravo, R., Gonzalez, J., Castro, A., Castilla, J., Martinez-Odriozola, P., Colmenero, M., Carballo, E., Suarez, D., et al. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.3.585 · Cited by 175
Pol, S., Lamorthe, B., Thi, N. T., Thiers, V., Carnot, F., Zylberberg, H., Berthelot, P., Bréchot, C., & Nalpas, B. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80341-3 · Cited by 165
Ridzon, R., Gallagher, K., Ciesielski, C., Mast, E. E., Ginsberg, M. B., Robertson, B. J., Luo, C.-C., & DeMaria, A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703273361304 · Cited by 161
Sánchez-Quijano, A., Andreu, J., Gavilán, F., Luque, F., Abad, M. A., Soto, B., Muñoz, J., Aznar, J. M., Leal, M., & Lissen, E. (1995) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01691375 · Cited by 159
Rumi, M. G., Colombo, M., Gringeri, A., & Mannucci, P. M. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-379 · Cited by 140
Severe hepatitis in three AIDS patients treated with indinavir
Bräu, N., Leaf, H. L., Wieczorek, R. L., & Margolis, D. M. (1997) · The Lancet · doi:10.1016/s0140-6736(05)62700-6 · Cited by 111
HCV genotypes in patients with liver disease of different stages and severity
Mangia, A., Cascavilla, I., Lezzi, G., et al. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80449-7 · Cited by 47
Cited by
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Global epidemiology of hepatitis C virus infection
Shepard, C. W., Finelli, L., & Alter, M. J. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70216-4 · Cited by 2,758
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Metadata
- Authors
- Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P., Katlama, C., & Poynard, T.
- Venue
- Hepatology
- Published
- 1999-10
- Volume
- 30
- Issue
- 4
- Pages
- 1054-1058
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2036313720
- Cited by
- 1,219
- References
- 21
- FWCI
- 23.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.